Sight Sciences Inc
NASDAQ:SGHT

Watchlist Manager
Sight Sciences Inc Logo
Sight Sciences Inc
NASDAQ:SGHT
Watchlist
Price: 4.66 USD -10.56% Market Closed
Market Cap: 234.4m USD
Have any thoughts about
Sight Sciences Inc?
Write Note

Intrinsic Value

SGHT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one SGHT stock under the Base Case scenario is 6.9 USD. Compared to the current market price of 4.66 USD, Sight Sciences Inc is Undervalued by 32%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SGHT Intrinsic Value
6.9 USD
Undervaluation 32%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Sight Sciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for SGHT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about SGHT?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Health Care Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Sight Sciences Inc

Provide an overview of the primary business activities
of Sight Sciences Inc.

What unique competitive advantages
does Sight Sciences Inc hold over its rivals?

What risks and challenges
does Sight Sciences Inc face in the near future?

Has there been any significant insider trading activity
in Sight Sciences Inc recently?

Summarize the latest earnings call
of Sight Sciences Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Sight Sciences Inc.

Provide P/S
for Sight Sciences Inc.

Provide P/E
for Sight Sciences Inc.

Provide P/OCF
for Sight Sciences Inc.

Provide P/FCFE
for Sight Sciences Inc.

Provide P/B
for Sight Sciences Inc.

Provide EV/S
for Sight Sciences Inc.

Provide EV/GP
for Sight Sciences Inc.

Provide EV/EBITDA
for Sight Sciences Inc.

Provide EV/EBIT
for Sight Sciences Inc.

Provide EV/OCF
for Sight Sciences Inc.

Provide EV/FCFF
for Sight Sciences Inc.

Provide EV/IC
for Sight Sciences Inc.

Show me price targets
for Sight Sciences Inc made by professional analysts.

What are the Revenue projections
for Sight Sciences Inc?

How accurate were the past Revenue estimates
for Sight Sciences Inc?

What are the Net Income projections
for Sight Sciences Inc?

How accurate were the past Net Income estimates
for Sight Sciences Inc?

What are the EPS projections
for Sight Sciences Inc?

How accurate were the past EPS estimates
for Sight Sciences Inc?

What are the EBIT projections
for Sight Sciences Inc?

How accurate were the past EBIT estimates
for Sight Sciences Inc?

Compare the revenue forecasts
for Sight Sciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Sight Sciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Sight Sciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Sight Sciences Inc compared to its peers.

Compare the P/E ratios
of Sight Sciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Sight Sciences Inc with its peers.

Analyze the financial leverage
of Sight Sciences Inc compared to its main competitors.

Show all profitability ratios
for Sight Sciences Inc.

Provide ROE
for Sight Sciences Inc.

Provide ROA
for Sight Sciences Inc.

Provide ROIC
for Sight Sciences Inc.

Provide ROCE
for Sight Sciences Inc.

Provide Gross Margin
for Sight Sciences Inc.

Provide Operating Margin
for Sight Sciences Inc.

Provide Net Margin
for Sight Sciences Inc.

Provide FCF Margin
for Sight Sciences Inc.

Show all solvency ratios
for Sight Sciences Inc.

Provide D/E Ratio
for Sight Sciences Inc.

Provide D/A Ratio
for Sight Sciences Inc.

Provide Interest Coverage Ratio
for Sight Sciences Inc.

Provide Altman Z-Score Ratio
for Sight Sciences Inc.

Provide Quick Ratio
for Sight Sciences Inc.

Provide Current Ratio
for Sight Sciences Inc.

Provide Cash Ratio
for Sight Sciences Inc.

What is the historical Revenue growth
over the last 5 years for Sight Sciences Inc?

What is the historical Net Income growth
over the last 5 years for Sight Sciences Inc?

What is the current Free Cash Flow
of Sight Sciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Sight Sciences Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Sight Sciences Inc

Current Assets 146.3m
Cash & Short-Term Investments 118.2m
Receivables 19.9m
Other Current Assets 8.2m
Non-Current Assets 3.4m
PP&E 2.7m
Other Non-Current Assets 640k
Current Liabilities 13.3m
Accounts Payable 1.9m
Accrued Liabilities 11.4m
Non-Current Liabilities 34.8m
Long-Term Debt 33.8m
Other Non-Current Liabilities 1m
Efficiency

Earnings Waterfall
Sight Sciences Inc

Revenue
79.4m USD
Cost of Revenue
-11.3m USD
Gross Profit
68.1m USD
Operating Expenses
-120m USD
Operating Income
-51.9m USD
Other Expenses
-432k USD
Net Income
-52.3m USD

Free Cash Flow Analysis
Sight Sciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In the second quarter, the company generated a total revenue of $21.4 million, demonstrating an 11% sequential growth but a 9% decrease compared to the previous year. The Surgical Glaucoma segment performed well with $20.2 million in revenue, an 11% increase sequentially, despite a 5% year-over-year decline. The company expects double-digit revenue growth in this segment in the second half of 2024. However, the Dry Eye segment faced a 46% revenue drop year-over-year due to a strategic shift. Guidance for full-year 2024 revenue has narrowed to $81-$83 million, with expectations of reduced third-quarter revenue due to seasonality and lower TearCare demand.

What is Earnings Call?
Fundamental Scores

SGHT Profitability Score
Profitability Due Diligence

Sight Sciences Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROIC is Increasing
Positive Revenue Growth Forecast
26/100
Profitability
Score

Sight Sciences Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

SGHT Solvency Score
Solvency Due Diligence

Sight Sciences Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Low D/E
53/100
Solvency
Score

Sight Sciences Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SGHT Price Targets Summary
Sight Sciences Inc

Wall Street analysts forecast SGHT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SGHT is 7.53 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

Lowest
Price Target
6.06 USD
30% Upside
Average
Price Target
7.53 USD
62% Upside
Highest
Price Target
10.5 USD
125% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SGHT?

Click here to dive deeper.

Dividends

Sight Sciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SGHT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SGHT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Sight Sciences Inc Logo
Sight Sciences Inc

Country

United States of America

Industry

Health Care

Market Cap

233.6m USD

Dividend Yield

0%

Description

Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. The company is headquartered in Menlo Park, California and currently employs 212 full-time employees. The company went IPO on 2021-07-15. The firm is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The firm operates through two segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment consists of sales of the OMNI surgical system. Its Dry Eye segment includes sales of the TearCare system and related components and accessories. The Company’s Surgical Glaucoma segment has a product portfolio, which features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision. Its Dry Eye segment has a product portfolio, which consists of the TearCare System for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids. The company sells both systems through a direct sales model.

Contact

CALIFORNIA
Menlo Park
3000 Sand Hill Road, Building 3, Suite 105
+14158890550.0
www.sightsciences.com

IPO

2021-07-15

Employees

212

Officers

Co-Founder, President, CEO & Director
Mr. Paul Badawi
Founder, CTO & Director
Dr. David Badawi M.D.
CFO & Treasurer
Ms. Alison Perry Bauerlein
Chief Commercial Officer
Mr. Matthew W. Link
Chief Operating Officer
Mr. Sam Boong Park
Chief Legal Officer
Mr. Jeremy B. Hayden
Show More
VP and Chief Ethics & Compliance Officer
Mr. Steve R. Tamayo Jr.
Chief Medical Officer
Dr. Reay H. Brown M.D.
Secretary
Mr. Stephen B. Thau J.D.
VP of Finance & Corporate Controller
Mr. Jim Rodberg
Show Less

See Also

Discover More
What is the Intrinsic Value of one SGHT stock?

The intrinsic value of one SGHT stock under the Base Case scenario is 6.9 USD.

Is SGHT stock undervalued or overvalued?

Compared to the current market price of 4.66 USD, Sight Sciences Inc is Undervalued by 32%.

Back to Top